The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development
- PMID: 22586314
- DOI: 10.1158/2159-8274.CD-11-0036
The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development
Abstract
Successful completion of the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial, reported in this issue of Cancer Discovery, is an important advance in the effort to improve clinical trial approaches to the simultaneous development of new therapeutics with matching diagnostic tests so that patients most likely to benefit from these therapies can be identified.
Comment on
-
The BATTLE trial: personalizing therapy for lung cancer.Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586319 Free PMC article. Clinical Trial.
Similar articles
-
A new BATTLE in the evolving war on cancer.Cancer Discov. 2011 Jun;1(1):14-6. doi: 10.1158/2159-8274.CD-11-0044. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586313
-
The BATTLE trial: personalizing therapy for lung cancer.Cancer Discov. 2011 Jun;1(1):44-53. doi: 10.1158/2159-8274.CD-10-0010. Epub 2011 Jun 1. Cancer Discov. 2011. PMID: 22586319 Free PMC article. Clinical Trial.
-
An overview of the design and conduct of the BATTLE trials.Chin Clin Oncol. 2015 Sep;4(3):33. doi: 10.3978/j.issn.2304-3865.2015.06.07. Chin Clin Oncol. 2015. PMID: 26408300 Review.
-
[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1. Bull Cancer. 2018. PMID: 29501208 Review. French.
-
Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.Pharmacoeconomics. 2017 Dec;35(12):1195-1209. doi: 10.1007/s40273-017-0563-8. Pharmacoeconomics. 2017. PMID: 28861770 Review.
Cited by
-
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.Clin Cancer Res. 2011 Nov 1;17(21):6634-40. doi: 10.1158/1078-0432.CCR-11-1105. Clin Cancer Res. 2011. PMID: 22046024 Free PMC article.
-
Cancer genomic research at the crossroads: realizing the changing genetic landscape as intratumoral spatial and temporal heterogeneity becomes a confounding factor.Cancer Cell Int. 2014 Nov 12;14(1):115. doi: 10.1186/s12935-014-0115-7. eCollection 2014. Cancer Cell Int. 2014. PMID: 25411563 Free PMC article.
-
Adaptive Clinical Trials: Overview of Early-Phase Designs and Challenges.Ther Innov Regul Sci. 2014 Jan;48(1):20-30. doi: 10.1177/2168479013513889. Epub 2013 Nov 26. Ther Innov Regul Sci. 2014. PMID: 28670507 Free PMC article.
-
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.Nat Rev Cancer. 2015 Nov;15(11):668-79. doi: 10.1038/nrc4019. Nat Rev Cancer. 2015. PMID: 26493647 Free PMC article. Review.
-
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4. Mol Carcinog. 2016. PMID: 26052929 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical